Harinad Maganti

Dr. Harinad (Hari) Maganti is a Research Scientist at Canadian Blood Services in Ottawa, Ontario. He completed a Master’s of Science in Microbiology at McMaster University and a Doctor of Philosophy in Immunology and Stem Cell Biology at the University of Ottawa. Dr. Maganti also received postdoctoral training in neuroscience at the Hospital for Sick Children as well as postdoctoral training in hematology and stem cell biology at Canadian Blood Services.

Research areas

• hematopoietic stem cell biology and therapies
• genetic engineering​
• epi-transcriptomics
• “off the shelf” immune cell therapies
• GMP manufacturing

Awards

• American Society of Hematology Scholar Award, 2024

Research interests

Dr. Harinad (Hari) Maganti focuses on hematopoietic stem cell transplantation (HSC) which is the only curative therapy for over 30 illnesses. However, HSCs are rare and the molecular mechanisms that govern HSC cell fate decisions are not well characterized. The overarching goal of his laboratory is to discover novel molecular programs/bioengineering technologies that lay the foundation for the development of new HSC products and universal adoptive cellular products for cellular therapy. We use unbiased systems biology and integrative approaches to build gene-regulatory networks (GRNs) using omics (bulk-RNA-seq, ATAC-seq, ChIP-seq, single-cell RNA-seq) data my team has generated in house. The GRNs are subsequently tested using reductionist approaches using CRISPR-Cas9 genome engineering technology to identify “drivers” of HSC fate.